These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 39085374)

  • 1. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
    He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
    PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
    Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.
    Liang X; Meng M; Qin S; Chen X; Li Y
    Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
    Li W; Wan L; Zhang J
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):293-301. PubMed ID: 38923910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
    Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
    BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
    Zheng Z; Chen H; Cai H; Zhu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
    Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
    Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Liu Y; Shao R
    Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    Peng J; Xu H; Liu Q
    PLoS One; 2024; 19(10):e0312133. PubMed ID: 39423210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
    Kang S; Wang X; Pan Z; Liu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
    Shao T; Zhao M; Tang W
    Front Oncol; 2022; 12():953671. PubMed ID: 36561521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.